$400M Strategic Investment Fuels MeiraGTx's Late-Stage Gene Therapy Commercialization
MGTX has more than doubled off its 52-week low of $6.62.
Summary
MeiraGTx announced a strategic investment of up to $400 million from Oberland Capital, which includes up to $375 million in royalty financing and an additional $10 million in equity. An initial $135 million of this capital has been funded. This largely non-dilutive funding, primarily through capped royalty payments, is earmarked to support the development and commercialization of its late-stage gene therapy programs, AAV2-hAQP1 and bota-vec, and will also be used to retire Perceptive Debt. This significant funding follows strong pipeline progress and prior financing activities, including a $200 million collaboration with Hologen and a public offering, further extending the company's financial runway beyond the previously reported H2 2028. The deal structure, with additional tranches tied to clinical data and regulatory approvals in 2027 and 2028, demonstrates strong confidence in the company's assets and provides substantial capital for critical commercialization efforts.
At the time of this announcement, MGTX was trading at $14.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $6.62 to $14.42. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.